(UroToday.com) Germline BRCA2 mutations are associated with more aggressive disease and poor clinical outcomes in prostate cancer. Small series have shown that prostate tumors in germline BRCA2 carriers present with more copy number alterations than tumors in non-carriers, including higher frequency of BRCA2 LOH, RB1 loss, and MYC amplification/gain.1 These aberrations may contribute to explaining the poor prognosis of germline BRCA2 prostate cancer patients. Most of the copy number alterations observed in these genes involve chromosomal segments larger than the genes themselves, which could be detected by multiple methods, including fluorescence in situ hybridization. At the prostate cancer session at the ESMO 2020 virtual annual meeting, Dr. Rebeca Lozano Mejorada and colleagues presented results of their case-control study to validate the prognostic value of germline BRCA2 and to explore the prognostic role of somatic BRCA2 loss, RB1 loss, and MYC amplification/gain, as well as other prostate cancer-related events.